Development of genetic prognostication models in newly diagnosed chronic lymphocytic leukaemia (CLL) patients

MRC · United Kingdom government procurement

This opportunity is now closed. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in people of European ancestry with more than 10 new cases per day in the UK alone. CLL has a highly heterogeneous clinical course and most patients are diagnosed with early stage asymptomatic disease that does not initially require treatment. Some patients live with asymptomatic disease for several years while others progress quickly requiring treatment. CLL is inherently incurable and a significant cause of mortality and morbidity, including high risk of recurrent infections.
CLL therapy has been transformed by highly effective and well tolerated B-cell receptor signalling pathway inhibitors (BCRi) which improve patient outcomes for those with advanced disease. Given the success in treating symptomatic CLL, focus has recently shifted towards addressing whether pre-emptive treatment can improve outcomes for patients with early-stage asymptomatic disease but at high-risk of progressing. Preliminary results from the German CLL12 trial report remarkable improvements in outcomes for high-risk CLL patients treated early with the BCRi ibrutinib, where time to death was 4-5 times longer in high-risk patients treated early. Despite this success, current prognostication models are inadequate and identify only a minority of high-risk patients.

The aim of this project is to develop accurate prognostication models for early-stage CLL in order to identify high-risk patients who might benefit from earlier treatment. To this end, we recently published a genome-wide association study utilising early-stage CLL cases and identified two common germline genetic variants that significantly associate with high-risk CLL (Lin et al, 2021, Nature Communications, 12: 665. doi: 10.1038/s41467-020-20822-9). These variants have prognostic value equivalent to established clinical markers and provide proof of concept that the incorporation of germline genetic markers can significantly improve prognostication models for the...

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedSeptember 30, 2022
Procurement stageActive solicitation
ClosedClosing date not published
StatusClosed — no longer accepting responses
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Browse Similar Open Opportunities in United Kingdom

Global Travel, Accommodation and Venue Management Services
Capital Programme Delivery Framework(s)
NEPRO Total Talent
Technology Products and Associated Services 3
Workforce Solution 2
Technology Products and Associated Services 3
GMCA 2201 NW Regional Children’s Services Contract
Integrated Partnerships Framework

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.